Valuation: Alkermes plc

Market Cap 9.1B 7.96B 7.3B 6.82B 12.92B 866B 13.11B 87.73B 34.1B 425B 34.16B 33.41B 1,468B P/E 2026 *
-144x
P/E 2027 * 91.4x
Enterprise Value 10.06B 8.8B 8.07B 7.54B 14.28B 958B 14.49B 97.01B 37.7B 470B 37.76B 36.94B 1,623B EV / Sales 2026 *
5.55x
EV / Sales 2027 * 5.18x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day+5.53%
1 week+3.31%
Current month+4.17%
1 month+32.09%
3 months+56.66%
6 months+93.14%
Current year+95.07%
1 week 50.96
Extreme 50.96
54.69
1 month 42.19
Extreme 42.1907
55.28
Current year 27
Extreme 27
55.28
1 year 25.16
Extreme 25.165
55.28
3 years 22.01
Extreme 22.01
55.28
5 years 21.24
Extreme 21.24
55.28
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Technology Officer

19,000 0.0114%
06-11Sell

Director

-2,000 0.0012%
06-03Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+5.53%+3.31%+88.21%+74.38% 9.1B
+1.70%+6.89%+2.76%+7.65% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+2.38%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.32%+1.58%+14.34%+19.26% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +2.06%+5.72%+73.52%+100.75% 25.14B
Weighted average by Cap. +1.94%+6.20%+89.11%+129.50%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.45B 1.36B 2.57B 172B 2.61B 17.47B 6.79B 84.68B 6.8B 6.65B 292B 1.89B 1.65B 1.52B 1.42B 2.69B 180B 2.73B 18.25B 7.09B 88.45B 7.1B 6.95B 305B
Net income -61.83M -54.08M -49.63M -46.33M -87.79M -5.89B -89.1M -596M -232M -2.89B -232M -227M -9.98B 108M 94.88M 87.08M 81.29M 154M 10.33B 156M 1.05B 407M 5.07B 407M 398M 17.5B
Net Debt 961M 841M 772M 720M 1.36B 91.51B 1.39B 9.27B 3.6B 44.94B 3.61B 3.53B 155B 702M 614M 563M 526M 996M 66.78B 1.01B 6.77B 2.63B 32.8B 2.63B 2.58B 113B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
02/07/26 US$54.58 +5.53% 1,653,919
01/07/26 US$51.72 -1.29% 1,638,365
30/06/26 US$52.40 -0.26% 2,958,468
29/06/26 US$52.53 -4.63% 2,940,864
26/06/26 US$55.08 +4.26% 7,563,601
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
54.58USD
Average target price
50.19USD
Spread / Average Target
-8.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock